Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 10Phase 1/2 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Lung Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × epothilone B × Clear all
NCT00171834 2014-02-05

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

Novartis

Phase 1/2 Completed
89 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00715013 2011-09-15

Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma

University of Zurich

Phase 1/2 Completed
9 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡